Canagliflozin (Invokana), an SGLT-2 Inhibitor, just received a new Food and Drug Administration (FDA) indication.

Adults with type 2 diabetes and diabetes kidney disease who take canagliflozin (Invokana) experience a reduction of:

• end-stage renal disease
• worsening kidney function
• cardiovascular death
• hospitalization for heart failure
  

This new indication is based on the results of the CREDENCE Trial, which was designed to see if canagliflozin had a renal vascular protective effect.

The trial enrolled over 4, 400 people with type 2 diabetes and GFRs between 30 and 90. The results clearly indicated several benefits.

Researchers observed a 32% risk reduction of end stage renal disease among patients who took canagliflozin (HR = 0.68), as well as a 28% risk reduction for starting dialysis, having a kidney transplant or experiencing renal death.

In a sub-group of the CREDENCE Trial, cardiovascular death for type 2 diabetes dropped by over 30% and in the CANVAS Study, there was a 33% drop in risk of hospitalization for heart failure.

Please see Oral Meds Pocketcard for side effects and precautions of canagliflozin and SGLT-2 Medications. In the most recent ADA Standards, two SGLT-2 Inhibitors, empagliflozin and canagliflozin are indicated for individuals with heart failure, chronic kidney disease and an elevated CV risk profile.

The use of these SGLT-2 Inhibitors offer hope and a new strategy to protect renal function and decrease heart disease risk in those living with diabetes.

For more information see this Helio Article on the new FDA indication for Canagliflozin.

Please see our GLP-1 Receptor Agonists and Injectibles Pocketcard for new oral GLP-1 tablet.

Get Your Updated PocketCards Here!

Download FREE Medication PocketCards on our website.

Purchase PocketCards – Updated physical PocketCards will ship out no later than October 18, 2019.

Download our FREE CDCES Coach App

---

Sign up for Diabetes Blog Bytes – we post one daily Blog Byte from Monday to Friday. And of course, Tuesday is our Question of the Week. It’s Informative and FREE!  Sign up below!

[yikes-mailchimp form=”1″]